These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15929815)

  • 1. [Sixty-four cases of percutaneous coronary angioplasty on saphenous vein bypass grafts].
    Li ZZ; Sidney L; Juergens CP; Zhu XL; Tao Y; Liu T; Wang S; Li Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Mar; 33(3):221-3. PubMed ID: 15929815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts.
    Baim DS; Wahr D; George B; Leon MB; Greenberg J; Cutlip DE; Kaya U; Popma JJ; Ho KK; Kuntz RE;
    Circulation; 2002 Mar; 105(11):1285-90. PubMed ID: 11901037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
    Karha J; Gurm HS; Rajagopal V; Fathi R; Bavry AA; Brener SJ; Lincoff AM; Ellis SG; Bhatt DL
    Am J Cardiol; 2006 Oct; 98(7):906-10. PubMed ID: 16996871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late outcomes after intervention of vein grafts in diabetics with abciximab use.
    Applegate RJ; Upadhya B; Little WC; Xenakis M; Gandhi SK; Baki TT; Kahl FR; Kutcher MA
    Int J Cardiol; 2006 Jul; 111(1):136-41. PubMed ID: 16226815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous revascularization of ostial saphenous vein graft stenoses.
    Abdel-Meguid AE; Whitlow PL; Simpfendorfer C; Sapp SK; Franco I; Ellis SG; Topol EJ
    J Am Coll Cardiol; 1995 Oct; 26(4):955-60. PubMed ID: 7560623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection.
    Jonas M; Stone GW; Mehran R; Hermiller J; Feldman R; Herrmann HC; Cox DA; Kuntz RE; Popma JJ; Rogers C;
    Eur Heart J; 2006 Apr; 27(8):920-8. PubMed ID: 16415300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does platelet glycoprotein IIb/IIIa receptor antibody improve in-hospital outcome of coronary stenting in high-risk thrombus containing lesions?
    Piamsomboon C; Wong PM; Mathur A; Singh D; Liu MW; Baxley WA; Iyer SS; Dean LS; Roubin GS
    Catheter Cardiovasc Interv; 1999 Apr; 46(4):415-20. PubMed ID: 10216005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention.
    Popma JJ; Cox N; Hauptmann KE; Reifart N; Virmani R; Emira K; Murphy S; Gibson CM; Grube E
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):125-34. PubMed ID: 12357506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts.
    Stone GW; Rogers C; Hermiller J; Feldman R; Hall P; Haber R; Masud A; Cambier P; Caputo RP; Turco M; Kovach R; Brodie B; Herrmann HC; Kuntz RE; Popma JJ; Ramee S; Cox DA;
    Circulation; 2003 Aug; 108(5):548-53. PubMed ID: 12874191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial.
    Mauri L; Cox D; Hermiller J; Massaro J; Wahr J; Tay SW; Jonas M; Popma JJ; Pavliska J; Wahr D; Rogers C
    J Am Coll Cardiol; 2007 Oct; 50(15):1442-9. PubMed ID: 17919563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic outcomes of embolic complications and strategies for distal embolic protection during percutaneous coronary intervention in saphenous vein grafts.
    Senter SR; Nathan S; Gupta A; Klein LW
    J Invasive Cardiol; 2006 Feb; 18(2):49-53. PubMed ID: 16446515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comeback for glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions for saphenous vein bypass grafts: may be for distal protection with filter-based devices?
    Niemelä KO
    Eur Heart J; 2006 Apr; 27(8):891-2. PubMed ID: 16484318
    [No Abstract]   [Full Text] [Related]  

  • 13. Embolic protection devices in saphenous percutaneous intervention.
    Morís C; Lozano I; Martín M; Rondán J; Avanzas P
    EuroIntervention; 2009 May; 5 Suppl D():D45-50. PubMed ID: 19736070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Pharmacologic" distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention.
    Fischell TA; Subraya RG; Ashraf K; Perry B; Haller S
    J Invasive Cardiol; 2007 Feb; 19(2):58-62. PubMed ID: 17268038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Direct percutaneous transluminal coronary angioplasty in patients with acute myocardial infarct treated at the Cardiac Center of the General Medical School Hospital in Prague: a 1-year retrospective study].
    Holm F; Kovárník T; Aschermann M; Simek S; Linhart A; Humhal J; Skulec R; Reznícek V
    Vnitr Lek; 2002 May; 48(5):373-9. PubMed ID: 12061202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous transluminal angioplasty of coronary saphenous vein bypass grafts.
    Marquis JF; Schwartz L; Brown R; Matushinsky E; Mickleborough L; Aldridge H; Henderson M
    Can J Surg; 1985 Jul; 28(4):335-7. PubMed ID: 3160452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saphenous vein graft intervention: a review.
    Hindnavis V; Cho SH; Goldberg S
    J Invasive Cardiol; 2012 Feb; 24(2):64-71. PubMed ID: 22294536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial.
    Cohen DJ; Murphy SA; Baim DS; Lavelle TA; Berezin RH; Cutlip DE; Ho KK; Kuntz RE;
    J Am Coll Cardiol; 2004 Nov; 44(9):1801-8. PubMed ID: 15519010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving role of glycoprotein (GP) IIb/IIIa receptor blockade during percutaneous coronary intervention of saphenous vein bypass grafts.
    D'Agate DJ; Patel S; Coppola JT; Ambrose JA
    J Invasive Cardiol; 2004 Sep; 16(9):500-3. PubMed ID: 15353833
    [No Abstract]   [Full Text] [Related]  

  • 20. [Coronary angioplasty in subgroups at risk: patients treated with bypass].
    La Vecchia L
    Ital Heart J Suppl; 2002 Jan; 3(1):16-25. PubMed ID: 11899571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.